Economic benefits associated with treatment-free survival of immuno-oncology agents among untreated patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Harrison, M; Regan, M; Atkins, M; Rao, S; Yang, S; Johansen, J; Du, E; Gu, C; Fadli, E; Betts, K; McDermott, D

Published Date

  • November 6, 2019

Published In

Volume / Issue

  • 7 /

Published By


  • 1

International Standard Serial Number (ISSN)

  • 2051-1426